Lebanon holds a distinctive position in the MENA pharmaceutical and healthcare landscape: a market defined by historically strong private healthcare infrastructure, a world-class academic medical tradition anchored at the American University of Beirut Medical Center (AUBMC), and a sophisticated pharmaceutical distribution culture built over decades. The Ministry of Public Health Lebanon (MoPH Lebanon) oversees pharmaceutical registration, drug pricing policy, and healthcare system regulation, maintaining an active regulatory framework even amid the broader economic challenges facing Lebanon. The Ordre des Médecins du Liban (OML — Lebanese Medical Order) provides the professional regulatory framework for physician practice, and its networks are essential for compliant healthcare professional engagement in research.
Lebanon's academic medical institutions — particularly AUBMC and LAU Medical Center-Rizk Hospital (affiliated with the Lebanese American University School of Medicine) — are among the most internationally recognised in the Arab world, publishing significantly in international medical literature and hosting senior KOLs who influence Levant-wide clinical practice. For pharmaceutical companies launching in Lebanon or seeking Levant-wide KOL insights, AUBMC and LAU Medical physician networks provide access to Arabic-English-French trilingual specialists across oncology, cardiology, endocrinology, infectious disease, and primary care. Lebanon's trilingual healthcare culture — operating across French, Arabic, and English — creates a unique research complexity that requires specialist multilingual instrument design and fieldwork management.
Despite Lebanon's economic challenges since 2019, the pharmaceutical market retains structural significance: Lebanon has a long-established generic pharmaceutical manufacturing capacity, a strong tradition of pharmaceutical export to the Levant and Gulf, and a physician community that continues to function as influential regional thought leaders. The post-crisis healthcare landscape has also created new research questions around healthcare access, supply chain resilience, and health insurance coverage gaps that are relevant to pharmaceutical market access and policy research. Companies seeking Levant-wide healthcare intelligence consistently include Lebanon for the quality of its physician and academic networks, even as the market's commercial size has contracted.